Experience

Revibe Technologies

• United States
• Biotechnology Research
• 1 - 100 Employee

• Chief Executive Officer

  • Mar 2021 - 2 years 10 months

  Wake Forest, North Carolina, United States CEO of Revibe Technologies (www.revibetech.com), a digital technology company developing a wearable device, focusing on leveraging psychology and incorporating big data, machine learning and dynamic patient feedback to improve the lives and outcomes of our users.



Amblyotech

• CEO

  • Sep 2013 - Apr 2020

  Phoenix, Arizona, United States Amblyotech is currently developing a patented digital therapy for the treatment of amblyopia or which is more commonly referred to as "lazy eye". Amblyopia currently inflicts 3% of children world-wide and if not corrected, is a leading cause of blindness in adults. Currently there are no adequate treatment options and Amblyotech is proceeding with clinical studies for regulatory approval internationally. For more information, please see www.amblyotech.com



Consulting Services

• Consultant

  • Apr 2011 - Jun 2017

  Consultant to the biotechnology and pharmaceutical industries in the areas of business development, licensing, marketing, finance, IPO's, M&A, collaborations, strategic alliances and product commercialization both nationally and internationally.



Latona Life Sciences Inc

• CEO

  • Apr 2007 - Apr 2011

  Responsible for the acquisition, financing, patents and clinical development of a novel late stage (Phase 2b/3) biologic treatment for patients suffering from Juvenile Rheumatoid Arthritis. •Incorporated company with initial management team •In-licensed the rights to “Oralgam” treatment for Juvenile Rheumatoid Arthritis •Obtained initial seed capital from investors •Developed clinical trial plan with management team and Scientific Advisory Board •Grant funding from National… Show more Responsible for the acquisition, financing, patents and clinical development of a novel late stage (Phase 2b/3) biologic treatment for patients suffering from Juvenile Rheumatoid Arthritis. •Incorporated company with initial management team •In-licensed the rights to “Oralgam” treatment for Juvenile Rheumatoid Arthritis •Obtained initial seed capital from investors •Developed clinical trial plan with management team and Scientific Advisory Board •Grant funding from National Institute for Health for clinical development Show less



Isotechnika Inc.

• Executive Vice President

  • Feb 1995 - Nov 2006

  Isotechnika is a publicly traded biotech company dedicated to the development of novel compounds for the treatment of auto-immune diseases and transplantation. Oversaw the corporate finance, licensing, patents, legal and business development for the company. Team leader for the commercialization of a series of diagnostic products internationally. •In licensed the original preclinical technology from a University. •Actively participated on the team which developed the compound from… Show more Isotechnika is a publicly traded biotech company dedicated to the development of novel compounds for the treatment of auto-immune diseases and transplantation. Oversaw the corporate finance, licensing, patents, legal and business development for the company. Team leader for the commercialization of a series of diagnostic products internationally. •In licensed the original preclinical technology from a University. •Actively participated on the team which developed the compound from Preclinical through Phase III trial. •Team leader that raised over $125 million through venture funds, IPO and PIPE financings. •Organized Initial Public Offering and maintained Sarbanes-Oxley compliance. •Negotiated over 100 licensing, distribution, manufacturing agreements including a key agreements with Roche Pharmaceuticals and Atrium Medical Devices. License with Roche was one the largest for a Phase I compound and provided for over $240 million in upfront and milestone payments plus royalties. •Project Head for the development, sales and marketing of the Diagnostics division which entered into international distribution and licensing agreements with local companies in China, Korea, Japan Europe, Middle East and South America. •Team leader for negotiations for a collaboration agreement with Glaxo for OEM licensing of diagnostic products. •Team leader for negotiations with Behring Diagnostics and Boehringer Mannheim for licensing of polyclonal antibody development. Show less